Perriello and coworkers analyzed a large cohort of NPM1-mutated AML patients and confirmed that CD123 is highly expressed in these leukemias, particularly at the level of the CD34+/CD38− cell population [22]. This evidence concerns the gene CD34 and acute myeloid leukemia.